Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)DivestmentsDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeSales of Property, Plant and Equipment
Growth Metrics
Income Statement
Others
Ratios

Takeda Pharmaceutical (TKPHF) Acquisitions (2018 - 2021)

Historic Acquisitions for Takeda Pharmaceutical (TKPHF) over the last 4 years, with Q4 2021 value amounting to -$194.6 million.

  • Takeda Pharmaceutical's Acquisitions changed N/A to -$194.6 million in Q4 2021 from the same period last year, while for Mar 2022 it was -$446.3 million, marking a year-over-year change of. This contributed to the annual value of -$442.4 million for FY2022, which is N/A changed from last year.
  • Takeda Pharmaceutical's Acquisitions amounted to -$194.6 million in Q4 2021.
  • Takeda Pharmaceutical's 5-year Acquisitions high stood at $652350.5 for Q3 2019, and its period low was -$26.3 billion during Q1 2019.
  • Moreover, its 4-year median value for Acquisitions was -$60.9 million (2018), whereas its average is -$3.0 billion.
  • Over the last 5 years, Takeda Pharmaceutical's Acquisitions had its largest YoY gain of 10107.18% in 2019, and its largest YoY loss of 9231.18% in 2019.
  • Takeda Pharmaceutical's Acquisitions (Quarter) stood at -$60.9 million in 2018, then surged by 99.85% to -$92014.2 in 2019, then plummeted by 2894.47% to -$2.8 million in 2020, then plummeted by 6963.45% to -$194.6 million in 2021.
  • Its last three reported values are -$194.6 million in Q4 2021, -$251.7 million for Q2 2021, and -$2.8 million during Q1 2020.